Oppenheimer analyst Esther Rajavelu raised her price target for Novocure to $97 from $85 following investor meetings with CEO Asaf Danziger, CFO Wilco Groenhuysen and others. In a research note to investors, Rajavelu says she now better appreciates the incremental Optune GBM revenue potential if used in conjunction with radiation therapy and that while a registrational trial and regulatory approval will be required prior to use, she views this incremental patient pool as "low hanging" opportunity beginning in 2023. Rajavelu maintains an Outperform rating.